Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
SPRC Catalyst Timeline
Dated clinical, regulatory and corporate events for SciSparc Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for SciSparc Ltd.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How SPRC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SCI-110 Small MoleculesNCT05126888 | Tourette Syndrome | Phase 2 | NOT YET_RECRUITING | 164 | Feb 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every SPRC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SCI-110 | Tourette Syndrome | Phase 2b | 2026-08-05 | average tic reduction of 21% across the entire participants sampleRead More | SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette SyndromeRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shrem ItschakDirector | Sell | -462 10,596 held | $10.00 | 06/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SPRC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SPRC for Q3 2026. | ||||
Ownership Trends
SPRC Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How SPRC ranks across every disease it competes in
SPRC News
SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company’s SAB
SciSparc Ltd. appointed Prof. Jacob Nagel to its Scientific Advisory Board, enhancing its focus on Agentic AI. Nagel, a former national security advisor, brings extensive experience in AI and cybersecurity. This move supports SciSparc's strategic entry into the Agentic AI sector, following the addition of another AI expert, Prof. Carmel Domshlak.
Read more →SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
SciSparc's subsidiary, NeuroThera Labs, reported progress in its FDA-approved Phase IIb trial for SCI-110, aimed at treating Tourette Syndrome. The company has completed product manufacturing and received batch release certification, enabling clinical trial material shipment. Patient enrollment is set to begin soon at three clinical sites across the USA, Germany, and Israel.
Read more →SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
SciSparc Ltd. is shifting its strategic focus towards Agentic AI technologies, particularly in cybersecurity and finance. This decision follows previous announcements and the establishment of a Scientific Advisory Board. The company aims to explore new opportunities within the Agentic AI ecosystem, although there are no guarantees of success or revenue generation from these efforts.
Read more →SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
SciSparc Ltd. is transitioning its focus to Agentic AI-powered technologies, particularly in cybersecurity and finance. This decision follows previous announcements regarding the establishment of a Scientific Advisory Board. The company aims to explore opportunities within the Agentic AI ecosystem, although there are no guarantees of successful outcomes from these initiatives.
Read more →SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
SciSparc's subsidiary, NeuroThera Labs, reported a successful quantum-enabled analysis of gene combinations using real-world clinical data. Their CliniQuantum platform achieved a 16.8-fold computational acceleration compared to traditional methods. The analysis identified over 22 million correlated gene triplets, showcasing the potential of quantum computing in biomedical research, although clinical validity remains unverified.
Read more →SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
SciSparc Ltd. announced that its subsidiary NeuroThera has expanded its U.S. patent portfolio through collaboration with Clearmind Medicine. The new patent applications cover combinations of PEA technology with LSD, ketamine, and ibogaine, targeting mental health disorders such as depression and PTSD. This collaboration aims to develop safer and more effective treatments for various neuropsychiatric conditions.
Read more →SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
SciSparc's subsidiary, NeuroThera Labs, is seeking FDA Orphan Drug Designation for SCI-110, a treatment for adult Tourette Syndrome. The engagement of RK Strategies aims to boost visibility and support regulatory pathways. SCI-110 has shown promising early clinical results, achieving a 21% tic reduction in Phase IIa trials, and is now advancing into Phase IIb trials across multiple academic centers.
Read more →SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has made significant progress in enrolling participants for the SCI-210 clinical trial aimed at treating autism spectrum disorder. With 26 out of 60 children enrolled, the trial evaluates the safety and efficacy of SCI-210, a combination of CBD and CannAmide™, over a 20-week period. The study is designed to assess whether this dual-compound treatment is more effective than CBD alone.
Read more →SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
SciSparc Ltd. has appointed Prof. Carmel Domshlak, a prominent AI researcher, to its Scientific Advisory Board, effective September 1, 2026. This move aims to bolster the company's capabilities in the Agentic AI market. Prof. Domshlak's extensive experience and accolades in AI research will support SciSparc's strategic focus on this rapidly evolving field.
Read more →SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
SciSparc Ltd. announced the publication of a patent application for a combination of MDMA and N-acylethanolamines aimed at treating PTSD, anxiety, and eating disorders. This development is part of a collaboration with Clearmind Medicine, which has resulted in a significant intellectual property portfolio. The FDA's recent guidance on psychedelic drugs further supports the regulatory framework for this collaboration.
Read more →SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
SciSparc Ltd. has announced that its subsidiary, NeuroThera Labs, completed a C$5.4 million financing round, with SciSparc contributing C$2.7 million. Following this investment, SciSparc holds approximately 44.6% of NeuroThera's shares, valued at C$30 million. The funds will be used for general working capital and corporate expenses.
Read more →SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
SciSparc Ltd.'s subsidiary, NeuroThera Labs, has been granted a Japanese patent for its innovative pharmacological combination aimed at enhancing the efficacy of 4-aminophenol derivatives. This patent is a significant milestone for NeuroThera as it expands its intellectual property and aims to modernize treatments for pain and fever. The combination therapy is designed to potentially lower dosing and mitigate side effects.
Read more →SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
SciSparc Ltd. announced the launch of a Phase IIb clinical trial for SCI-110, a cannabinoid-based treatment for Tourette Syndrome, at Yale Child Study Center. The trial aims to evaluate the efficacy and safety of SCI-110, building on positive results from a previous Phase IIa study. The study is also being conducted at sites in Germany and Israel, addressing a significant unmet medical need.
Read more →SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
SciSparc Ltd. announced a significant achievement by its subsidiary, NeuroThera Labs, in developing a hybrid quantum-classical workflow for clinical data analytics. This platform can process real-world clinical data and generate interpretable insights, enhancing the analysis of complex biomedical datasets. Future plans include optimizing algorithms and expanding dataset capabilities.
Read more →SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has validated a quantum sampling workflow for clinical data analysis. This platform, developed in collaboration with an S&P 500 company, aims to enhance the analysis of large-scale clinical datasets. The validation marks a significant step toward advanced quantum-enabled analytical capabilities in healthcare.
Read more →SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
SciSparc Ltd. has announced its decision to enter the agentic AI market and establish a Scientific Advisory Board focused on AI and cybersecurity. The company is currently evaluating opportunities and engaging in discussions with several firms in the AI sector. This move reflects SciSparc's strategic growth initiatives while continuing its focus on cannabinoid pharmaceuticals.
Read more →SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
SciSparc Ltd. has announced the initiation of a Phase IIb clinical trial for SCI-110, a cannabinoid-based treatment for Tourette Syndrome, at Hannover Medical School in Germany. This trial follows positive results from a Phase IIa study, which indicated a significant reduction in tic severity. The study aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adults aged 18-65.
Read more →SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has completed the acquisition of a 54% interest in CliniQuantum. This acquisition, valued at approximately CAD$9.46 million, aims to leverage CliniQuantum's technology for improving clinical trial outcomes. The deal includes potential earn-out payments based on future milestones, highlighting the strategic focus on central nervous system disorders.
Read more →SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, received conditional regulatory approval from the TSX for acquiring a 54% interest in CliniQuantum. The acquisition involves issuing approximately 56.6 million common shares of NeuroThera to CliniQuantum's shareholders. This strategic move aims to enhance NeuroThera's capabilities in developing novel treatments for central nervous system disorders.
Read more →SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
SciSparc Ltd. has announced a collaboration with NeuroThera Labs and Clearmind Medicine, resulting in a patent application for a new therapy targeting major depressive disorder. This innovative treatment combines MEAI and PEA, potentially offering a non-hallucinogenic alternative to traditional antidepressants. The patent filing highlights the promise of this combination in addressing depression, a major global health concern.
Read more →